Aziyo Biologics to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
- SILVER SPRING, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
- 05/03/2023
|
Aziyo Biologics, Inc. (AZYO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
- Aziyo Biologics, Inc. (AZYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 04/05/2023
|
Aziyo Biologics, Inc. (AZYO) Q4 2022 Earnings Call Transcript
- Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Josh Jennings - TD Cowen & Company Operator Good day, ladies and gentlemen, and welcome to the Aziyo Biologics Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.
- 03/22/2023
|
ACER's Stock Down on Failure of Phase II Study, Cash Updates
- ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
- 03/20/2023
|
Aziyo Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 22, 2023
- SILVER SPRING, Md., March 15, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 22, 2023. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
- 03/15/2023
|
Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference
- SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place on Monday, March 6, 2023, at 9:50 am ET.
- 02/27/2023
|
Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know
- Aziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 01/26/2023
|
Aziyo Biologics to Participate in Upcoming Investor Conferences
- SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that management will be participating in the following investor conferences:
- 11/21/2022
|
Aziyo Biologics, Inc. (AZYO) Q3 2022 Earnings Call Transcript
- Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Matt Steinberg - Fin Partners Randy Mills - CEO Matt Ferguson - CFO Conference Call Participants Josh Jennings - Cowen Simran Kaur - Piper Sandler David Rescott - Truist Securities Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Aziyo Biologics Third Quarter 2022 Earnings Conference Call.
- 11/15/2022
|
Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Tops Revenue Estimates
- Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -10.61% and 1.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/14/2022
|
Aziyo Biologics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
- SILVER SPRING, Md., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022 at 10:30 am ET / 7:30 am PT.
- 08/17/2022
|
Aziyo Biologics (AZYO) CEO Randy Mills on Q2 2022 Results - Earnings Call Transcript
- Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Leigh Salvo - IR Kevin Rakin - Executive Chairman Randy Mills - CEO Matthew Ferguson - CFO Conference Call Participants Josh Jennings - Cowen David Rescott - Truist Ross Osborn - Cantor Fitzgerald Operator Good day. And thank you for standing by.
- 08/13/2022
|
Aziyo Biologics to Report Second Quarter 2022 Financial Results on August 11, 2022
- SILVER SPRING, Md., July 28, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it will release second quarter 2022 financial results after market close on Thursday, August 11, 2022. Members of the Company's management team will host a conference call and webcast with accompanying slides starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
- 07/28/2022
|
Is Aziyo Biologics (AZYO) Outperforming Other Medical Stocks This Year?
- Here is how Aziyo Biologics, Inc. (AZYO) and AMN Healthcare Services (AMN) have performed compared to their sector so far this year.
- 07/20/2022
|
Aziyo Biologics, Inc. (AZYO) Moves 7.8% Higher: Will This Strength Last?
- Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 06/27/2022
|
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q1 2022 Results - Earnings Call Transcript
- Aziyo Biologics, Inc. (NASDAQ:AZYO ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Ronald Lloyd – President and Chief Executive Officer Matthew Ferguson – Chief Financial Officer Leigh Salvo – Investor Relations, Gilmartin Group, LLC Conference Call Participants David Rescott – Truist Securities Operator Thank you for standing by and welcome to Aziyo Biologics Q1 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 05/09/2022
|
Aziyo Biologics, Inc. (AZYO) Reports Q1 Loss, Tops Revenue Estimates
- Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of 3.23% and 6.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/09/2022
|
Aziyo Biologics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022
- SILVER SPRING, Md., April 25, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter 2022 earnings results after market close on Monday, May 9, 2022. Management will host a conference call to review the Company's financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.
- 04/25/2022
|
Aziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor Conference
- SILVER SPRING, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.
- 03/31/2022
|
Aziyo Biologics, Inc. (AZYO) Reports Q4 Loss, Lags Revenue Estimates
- Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -28.13% and 2.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/03/2022
|
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2021 Results - Earnings Call Transcript
- Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2021 Results - Earnings Call Transcript
- 03/03/2022
|
Aziyo Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022
- SILVER SPRING, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its fourth quarter and full year 2021 earnings results after market close on Thursday, March 3, 2022. Management will host a conference call to review the Company's financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.
- 02/17/2022
|
All You Need to Know About Aziyo Biologics, Inc. (AZYO) Rating Upgrade to Buy
- Aziyo Biologics, Inc. (AZYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 02/14/2022
|
Aziyo Biologics to Present at the H.C. Wainwright Bioconnect Virtual Conference
- SILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference.
- 12/27/2021
|
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q3 2021 Results - Earnings Call Transcript
- Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Misses Revenue Estimates
- Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -32.79% and -0.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2021
|
Aziyo Biologics Provides Business Update and Preliminary Third Quarter 2021 Revenue Results and Announces Timing for Third Quarter 2021 Financial Results
- SILVER SPRING, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it was informed by Medtronic that, after conducting a thorough review of customer and patient needs, Medtronic has made the decision to cease distribution of Cellular Bone Matrix (CBM) products. As a result of this decision, the two companies are working toward a mutual termination of their FiberCel distribution agreement.
- 10/25/2021
|
Aziyo Biologics to Participate in the 2021 Cantor Global Healthcare Conference
- SILVER SPRING, Md., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming 2021 Cantor Global Healthcare Conference.
- 09/15/2021
|
Aziyo Biologics Appoints Peter G. Edwards as General Counsel
- SILVER SPRING, Md., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the appointment of Peter G. Edwards as General Counsel.
- 08/31/2021
|
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q2 2021 Results - Earnings Call Transcript
- Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q1 2021 Results - Earnings Call Transcript
- Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Aziyo Biologics Reports First Quarter 2021 Financial Results and Increases 2021 Revenue Guidance
- SILVER SPRING, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three months ended March 31, 2021.
- 05/04/2021
|
Aziyo Biologics to Participate in the Truist Securities Life Sciences Summit
- SILVER SPRING, Md., April 26, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Truist Securities Life Sciences Summit.
- 04/26/2021
|
Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2020 Results - Earnings Call Transcript
- Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2020 Results - Earnings Call Transcript
- 03/01/2021
|
Aziyo Biologics Reports Fourth Quarter and Full Year 2020 Financial Results
- SILVER SPRING, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the fourth quarter and full year ended December 31, 2020.
- 03/01/2021
|
Aziyo Biologics to Participate in the Cowen 41st Annual Health Care Conference
- SILVER SPRING, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Cowen 41st Annual Health Care Conference.
- 02/18/2021
|
Aziyo Biologics Announces First Patient Enrolled in HEAL Study
- SILVER SPRING, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today the first patient enrolled in the HEAL Study, investigating the biologic and clinical effects of device envelopes which are placed around cardiovascular implantable electronic devices (“CIEDs”) at the time of implantation surgery.
- 02/17/2021
|
Aziyo Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021
- SILVER SPRING, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its fourth quarter and full year earnings results after market close on Monday, March 1, 2021. Management will host a conference call to review the Company's financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.
- 02/15/2021
|
Aziyo Biologics Announces Product Design Completion for its Next Generation CanGaroo® Envelope for Implantable Electronic Devices
- SILVER SPRING, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today product design completion for CanGaroo® with antibiotics, the next generation of the Company's CanGaroo Envelope.
- 02/11/2021
|
Aziyo Biologics Announces Updated CanGaroo® Envelope Label in European Markets to Allow for Hydration in an Antibiotic Solution
- SILVER SPRING, Md., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it has received CE Mark approval for updated labeling of the Company's biological CanGaroo® Envelope to allow for the addition of the antibiotic gentamicin. While the indications of the CanGaroo Envelope remain unchanged, this approval now permits the envelope to be hydrated in a gentamicin solution during device preparation prior to implantation at the discretion of the prescribing physician. Pre-clinical testing has demonstrated hydrating the CanGaroo Envelope in gentamicin prior to use can reduce or inhibit bacterial growth.
- 01/28/2021
|
